ImmunoVaccine Technologies (IVT), a vaccine development company, has been selected as one of the winners of Canada's Top 10 Life Sciences Companies (WWW.TOPCANADIANCOMPANIES.CA).

Winners are chosen by an independent expert panel of Canadian and U.S. venture capitalists. This award gives IVT the opportunity to present at the 12th Annual Ottawa Venture and Technology Summit on October 8, 2008 (WWW.OTTAWAVTS.COM).

"We have a technology that gives impressive results when applied to therapeutic cancer and infectious disease vaccines and, as one of Canada's Top 10™, we now have an exclusive opportunity to present to top tier venture capitalists," said Dr. Randal Chase, president and CEO of IVT.

Canada's Top 10 is organized by OCRI (Ottawa Centre for Research and Innovation). Originally developed to promote the 10 most promising life sciences companies from across Canada to Canadian and international investors and partners, the competition now showcases Canada's life sciences, cleantech and technology sectors. Of the 30 winning companies, only IVT has been chosen from Atlantic Canada.

Working in partnership with Canadian Consulates in Boston, New York City, San Diego and San Francisco, winning companies will participate in targeted investment forums in each city, providing them with an opportunity to meet with venture capital investors who have expressed an active interest in financing these companies. Since its inception in 1999, competition alumni have secured more than $522 million in venture capital financing.

About IVT (WWW.IMMUNOVACCINE.COM)
ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine development company. Through its own biotech research, patented VacciMax® and DepoVax™ technologies, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world. In January 2008, IVT licensed its technology to Pfizer Animal health, marking a pivotal step in achieving its vision of delivering breakthrough vaccines.

For more information, please contact:

Brian Lowe, Vice President
ImmunoVaccine Technologies Inc.
T 902.492.1819 
BL.IVT@IMMUNOVACCINE.COM

Jennifer Ayotte, Communications
T 902.209.4704
JAYOTTE@IMPACTCOMMUNICATIONS.CA

Halifax, Nova Scotia, September 30, 2008